Ascidian Therapeutics Announces Leadership Transition
Daniel Rosan Appointed President Michael Ehlers to Continue as Board Chair BOSTON, July 21, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a planned leadership transition as Ascidian heads into the next...
Daniel Rosan Appointed President Michael Ehlers to Continue as Board Chair BOSTON, July 21, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a planned leadership transition as Ascidian heads into the next...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.